Cathie Wood Just This Biotech Bet: Reading the Signals
ARKK and ARKG are back in the biotech spotlight as Cathie Wood makes new bets after a setback in a key antisense stoc...
On this Genomics page, explore 3 earnings and outlook articles on SOPH, VCYT, and PACB to gauge growth and risk. Use these insights to time trades and strengthen your portfolio decisions.
5 articlesARKK and ARKG are back in the biotech spotlight as Cathie Wood makes new bets after a setback in a key antisense stoc...
A CEO’s large stock sale can spark questions about a company’s trajectory. This guide breaks down what genomics sells...
As PacBio lays out its Q1 2026 results, investors hunt for catalysts, cadence, and cash runway signals. This guide tr...
In 2025, Sophia Genetics is at a crossroads between expanding its software platform and tightening its financial disc...
As Veracyte approaches its Q4 2025 earnings, investors want a clear view of revenue momentum, margins, and reimbursem...